Envestnet Portfolio Solutions Inc. bought a new position in shares of TransMedics Group, Inc. (NASDAQ:TMDX – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 4,171 shares of the company’s stock, valued at approximately $559,000.
Several other institutional investors have also recently bought and sold shares of the business. Opal Wealth Advisors LLC purchased a new stake in shares of TransMedics Group in the second quarter valued at about $26,000. Smartleaf Asset Management LLC increased its holdings in TransMedics Group by 44.3% during the first quarter. Smartleaf Asset Management LLC now owns 440 shares of the company’s stock worth $30,000 after buying an additional 135 shares during the last quarter. Quarry LP increased its holdings in TransMedics Group by 88.5% during the first quarter. Quarry LP now owns 592 shares of the company’s stock worth $40,000 after buying an additional 278 shares during the last quarter. Sound Income Strategies LLC bought a new position in TransMedics Group during the second quarter worth about $48,000. Finally, Hager Investment Management Services LLC boosted its position in TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company’s stock worth $50,000 after purchasing an additional 205 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.
Analysts Set New Price Targets
TMDX has been the subject of a number of research reports. Morgan Stanley increased their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Weiss Ratings reiterated a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday. Canaccord Genuity Group reiterated a “buy” rating and set a $142.00 target price on shares of TransMedics Group in a research report on Tuesday, October 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of TransMedics Group in a research report on Monday, August 25th. Seven equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $127.18.
TransMedics Group Price Performance
TMDX stock opened at $120.13 on Wednesday. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $145.50. The firm has a market capitalization of $4.10 billion, a P/E ratio of 62.24 and a beta of 2.08. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61. The firm has a 50 day moving average of $116.15 and a 200-day moving average of $114.35.
TransMedics Group (NASDAQ:TMDX – Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million during the quarter, compared to analyst estimates of $146.64 million. During the same period in the previous year, the business posted $0.35 earnings per share. TransMedics Group’s revenue for the quarter was up 37.7% on a year-over-year basis. TransMedics Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.
TransMedics Group Profile
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
See Also
- Five stocks we like better than TransMedics Group
- Best Energy Stocks – Energy Stocks to Buy Now
- 2 Ways to Trade Qualcomm Ahead of November’s Earnings
- What Are Earnings Reports?
- Lululemon: 2 Signs the Bottom Is In, and 1 Sign It Isn’t
- Do ETFs Pay Dividends? What You Need to Know
- Got 1K to Invest? These 3 Stocks Are Still Attractive Buys
Want to see what other hedge funds are holding TMDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TransMedics Group, Inc. (NASDAQ:TMDX – Free Report).
Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.